Last reviewed · How we verify
NCT00091299
An Open Label, Non Randomized , One Sequence, Add-On Study to Investigate the Effects of PTK787/ZK 222584 on the Pharmacokinetics and Pharmacodynamics of Warfarin at Steady-States in Cancer Patients
Phase 1 trial testing warfarin in Unspecified Adult Solid Tumor, Protocol Specific in 24 participants. Completed in 1 August 2012.
1 August 2012
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 May 2004 |
| Primary completion | 1 August 2012 |
| Estimated completion | 1 August 2012 |
| Sites | 1 location across United States |
Drugs / interventions tested
- warfarin (warfarin) — full drug profile →
Conditions studied
- Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
18 and older, any sex, with Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To evaluate acute and chronic changes in INR when Warfarin is co-administered with PTK787/ZK 222584
Time frame: 2 weeks
Sponsor's own description
RATIONALE: Vatalanib may stop the growth of tumor cells by stopping blood flow to the tumor. Warfarin may be effective in preventing the formation of blood clots in patients who are undergoing treatment for advanced solid tumors. PURPOSE: This phase I trial is studying how well giving warfarin together with vatalanib works in treating patients with advanced solid tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).
Maxwell WD, Bennett CL. · · 2012 · cited 9× · PMID 23111863 · DOI 10.1055/s-0032-1328893
Verify or expand the search:
- PubMed search for NCT00091299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of warfarin
Trials testing the same drug.
- NCT05815680 — A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overw · Phase 1 · completed
- NCT05795062 — Treatment Patterns Among Patients With Venous Thromboembolism in the United States · completed
- NCT04198844 — The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Po · withdrawn
- NCT03536611 — Dabigatran Versus Warfarin With NVAF Who Undergo PCI · Phase 4 · unknown
- NCT03572972 — Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea · completed
Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific
Currently open trials in the same condition.
- NCT02112565 — RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Stand · Phase 1 · active not recruiting
- NCT02293954 — Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · NA · active not recruiting
- NCT00477958 — Assessment Tool for Older Patients With Cancer · NA · active not recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00091299 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 3 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00091299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing